1. Butler MS, Hansford KA, Blaskovich MA, Halai R, Cooper MA. Glycopeptide antibiotics: back to the future. J Antibiot (Tokyo) 2014;67:631–644.
3. Choi WS, Kim WJ. Vancomycin and teicoplanin. In: The Korean Society of Infectious Diseases, ed. Textbook of guideposts to antimicrobial. 4th ed. Paju: Koonja Publishing Inc., 2016:298–309.
4. McCormick MH, Mcguire JM, Pittenger GE, Pittenger RC, Stark WM. Vancomycin, a new antibiotic. I. Chemical and biologic properties. Antibiot Annu 1955;3:606–611.
5. Bardone MR, Paternoster M, Coronelli C. Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. II. Extraction and chemical characterization. J Antibiot (Tokyo) 1978;31:170–177.
7. Judice JK, Pace JL. Semi-synthetic glycopeptide antibacterials. Bioorg Med Chem Lett 2003;13:4165–4168.
8. Candiani G, Abbondi M, Borgonovi M, Romanò G, Parenti F. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother 1999;44:179–192.
9. Bouza E, Burillo A. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains. Int J Antimicrob Agents 2010;36:401–407.
11. Ramos-Martín V, Johnson A, McEntee L, et al. Pharmacodynamics of teicoplanin against MRSA. J Antimicrob Chemother 2017;72:3382–3389.
12. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325–327.
13. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020;77:835–864.
15. Kim SH, Kang CI, Huh K, et al. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy. Eur J Clin Microbiol Infect Dis 2019;38:2113–2120.
16. Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986;11:257–282.
17. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011;50:99–110.
18. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006;42(Suppl 1):S35–S39.
19. Larsson AJ, Walker KJ, Raddatz JK, Rotschafer JC. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother 1996;38:589–597.
21. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004;43:925–942.
22. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011;52:975–981.
28. Suzuki Y, Kawasaki K, Sato Y, et al. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia. Chemotherapy 2012;58:308–312.
29. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;49:507–514.
30. Park SJ, Lim NR, Park HJ, et al. Evaluation of risk factors for vancomycin-induced nephrotoxicity. Int J Clin Pharm 2018;40:1328–1334.
31. Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev 2014;77:50–57.
33. Turner RB, Kojiro K, Shephard EA, et al. Review and validation of bayesian dose-optimizing software and equations for calculation of the vancomycin area under the curve in critically ill patients. Pharmacotherapy 2018;38:1174–1183.
34. Drennan P, Doogue M, van Hal SJ, Chin P. Bayesian therapeutic drug monitoring software: past, present and future. Int J Pharmacokinet 2018;3:109–114.
36. Diaz R, Afreixo V, Ramalheira E, Rodrigues C, Gago B. Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections-a systematic review and meta-analysis. Clin Microbiol Infect 2018;24:97–104.
38. Hsu DI, Hidayat LK, Quist R, et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 2008;32:378–385.
39. Steinmetz T, Eliakim-Raz N, Goldberg E, Leibovici L, Yahav D. Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis. Clin Microbiol Infect 2015;21:665–673.
40. Clark L, Skrupky LP, Servais R, Brummitt CF, Dilworth TJ. Examining the relationship between vancomycin area under the concentration time curve and serum trough levels in adults with presumed or documented staphylococcal infections. Ther Drug Monit 2019;41:483–488.
42. Liang X, Fan Y, Yang M, et al. A prospective multicenter clinical observational study on vancomycin efficiency and safety with therapeutic drug monitoring. Clin Infect Dis 2018;67(Suppl 2):S249–S255.
43. Gilbert DN, Chambers HF, Eliopoulos GM, et al. Table 17A. In: Gilbert DN, Chambers HF, Eliopoulos GM, eds. The sanford guide to antimicrobial therapy 2019: 50 years: 1969-2019. 49th ed. Sperryville Virginia: Antimicrobial Therapy, 2019:234–249.
44. Kim SH, Kang CI, Lee SH, et al. Weight-based vancomycin loading strategy may not improve achievement of optimal vancomycin concentration in patients with preserved renal function. J Chemother 2021;33:56–61.
45. Baptista JP, Sousa E, Martins PJ, Pimentel JM. Augmented renal clearance in septic patients and implications for vancomycin optimisation. Int J Antimicrob Agents 2012;39:420–423.
46. Crass RL, Dunn R, Hong J, Krop LC, Pai MP. Dosing vancomycin in the super obese: less is more. J Antimicrob Chemother 2018;73:3081–3086.
48. Vuagnat A, Stern R, Lotthe A, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther 2004;29:351–357.
49. Hanrahan T, Whitehouse T, Lipman J, Roberts JA. Vancomycin-associated nephrotoxicity: a meta-analysis of administration by continuous versus intermittent infusion. Int J Antimicrob Agents 2015;46:249–253.
50. Verrall AJ, Llorin R, Tam VH, et al. Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections. J Antimicrob Chemother 2012;67:2970–2973.
51. Baker DS, Waldrop B, Arnold J. Compatibility and stability of cefotaxime, vancomycin, and ciprofloxacin in antibiotic lock solutions containing heparin. Int J Pharm Compd 2010;14:346–349.
52. Choi YC, Saw S, Soliman D, et al. Intravenous vancomycin associated with the development of nephrotoxicity in patients with class iii obesity. Ann Pharmacother 2017;51:937–944.
53. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998;54:621–625.
55. Mahmoud LB, Chaabouni Y, Ghozzi H, et al. Optimization of therapeutic drug monitoring of vancomycin in patients with chronic hemodialysis. Clin Nephrol 2017;88:198–204.
57. Bierman MH, Needham-Walker CA, Hammeke M, Egan JD. Vancomycin therapy for serious staphylococcal infections in chronic hemodialysis patients. J Dial 1980;4:179–184.
58. Crawford BS, Largen RF, Walton T, Doran JJ. Once-weekly vancomycin for patients receiving high-flux hemodialysis. Am J Health Syst Pharm 2008;65:1248–1253.
59. De Bock V, Verbeelen D, Maes V, Sennesael J. Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration. Nephrol Dial Transplant 1989;4:635–639.
60. Mason NA, Neudeck BL, Welage LS, Patel JA, Swartz RD. Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration. Clin Nephrol 2003;60:96–104.
61. Pallotta KE, Manley HJ. Vancomycin use in patients requiring hemodialysis: a literature review. Semin Dial 2008;21:63–70.
62. Pollard TA, Lampasona V, Akkerman S, et al. Vancomycin redistribution: dosing recommendations following high-flux hemodialysis. Kidney Int 1994;45:232–237.
63. Covajes C, Scolletta S, Penaccini L, et al. Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy. Int J Antimicrob Agents 2013;41:261–266.
64. Yang CJ, Wu CW, Wu CC. Effect of extracorporeal membrane oxygenation on the new vancomycin dosing regimen in critically ill patients receiving continuous venovenous hemofiltration. Ther Drug Monit 2018;40:310–314.
66. Choi R, Woo HI, Park HD, Lee SY. A nationwide utilization survey of therapeutic drug monitoring for five antibiotics in South Korea. Infect Drug Resist 2019;12:2163–2173.
67. Jung Y, Song KH, Cho Je, et al. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents 2014;43:179–183.
69. Harding I, Sorgel F. Comparative pharmacokinetics of teicoplanin and vancomycin. J Chemother 2000;12(Suppl 5):15–20.
70. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003;17:479–501.
71. Kuti JL, Kiffer CR, Mendes CM, Nicolau DP. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect 2008;14:116–123.
72. Matsumoto K, Watanabe E, Kanazawa N, et al. Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections. Clin Pharmacol 2016;8:15–18.
73. Hagihara M, Umemura T, Kimura M, Mori T, Hasegawa T, Mikamo H. Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus. J Infect Chemother 2012;18:10–16.
74. Matsumoto K, Kanazawa N, Ikawa K, et al. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections. J Infect Chemother 2010;16:193–199.
75. Harding I, MacGowan AP, White LO, Darley ES, Reed V. Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother 2000;45:835–841.
78. Nakamura A, Takasu O, Sakai Y, et al. Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections. J Infect Chemother 2015;21:449–455.
79. Sato M, Chida K, Suda T, et al. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level. J Infect Chemother 2006;12:185–189.
80. Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 2000;39:167–183.
82. Henry P, Rob S. Chapter T. In: Paw H, Shulman R, eds. Handbook of drugs in intensive care: an A-Z guide. 6th ed. Cambridge: Cambridge University Press, 2019:276.
84. Papaioannou MG, Marinaki S, Pappas M, et al. Pharmacokinetics of teicoplanin in patients undergoing chronic haemodialysis. Int J Antimicrob Agents 2002;19:233–236.
85. Bonati M, Traina GL, Rosina R, Buniva G. Pharmacokinetics of a single intravenous dose of teicoplanin in subjects with various degrees of renal impairment. J Antimicrob Chemother 1988;21(Suppl A):29–37.
86. Wolter K, Claus M, Wagner K, Fritschka E. Teicoplanin pharmacokinetics and dosage recommendations in chronic hemodialysis patients and in patients undergoing continuous veno-venous hemodialysis. Clin Nephrol 1994;42:389–397.
87. Thalhammer F, Rosenkranz AR, Burgmann H, et al. Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes. Wien Klin Wochenschr 1997;109:362–365.
88. Shiraishi Y, Okajima M, Sai Y, Miyamoto K, Inaba H. Elimination of teicoplanin by adsorption to the filter membrane during haemodiafiltration: screening experiments for linezolid, teicoplanin and vancomycin followed by in vitro haemodiafiltration models for teicoplanin. Anaesth Intensive Care 2012;40:442–449.
89. Yagasaki K, Gando S, Matsuda N, et al. Pharmacokinetics of teicoplanin in critically ill patients undergoing continuous hemodiafiltration. Intensive Care Med 2003;29:2094–2095.
90. Lim SK, Lee SA, Kim CW, Kang E, Choi YH, Park I. High variability of teicoplanin concentration in patients with continuous venovenous hemodiafiltration. Hemodial Int 2019;23:69–76.
91. Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 2007;46:997–1038.